However, as the combined treatment with IFN-α and tocilizumab induced higher DR4 expression compared with that of IFN-α treatment alone, it is suggested that IL-6-induced SOCS3 has, at least in part, a role in DR4 degradation in RCC cells. Here, SOCS3 is linked to renal cell carcinoma.